← Markets

Natera, Inc.

NTRA · NASDAQ

Market closed$271.39$1.56 (+0.58%)After hours $271.38 · 0.00%

Key statistics

Previous close$269.83
Open$267.50
Day high$272.37
Day low$262.00
52-week high$288.04
52-week low$131.81
Market cap38.87B
Volume979.39K
Average volume1.54M
P/E ratio-170.69
Forward P/E—
EPS-1.59
Dividend yield0.00%

Market context

Why it moved

Natera's stock edged higher, supported by continued investor confidence following a string of positive catalysts including Bernstein SocGen's outperform rating resumption, Signatera's IVDR certification in Europe, regulatory approval in Japan, and new clinical data published in JAMA Oncology, keeping the stock trading near its 52-week highs.

FacebookInvesting.comTracksideviewSubstackInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Natera edged higher, outperforming the broader healthcare sector (XLV closed lower) as investors digested new peer-reviewed JAMA Oncology data showing its Signatera MRD test can identify colorectal liver metastasis patients who benefit from adjuvant chemotherapy — strengthening the clinical case for broader adoption. Adding to the narrative, Bernstein SocGen resumed coverage with an outperform rating citing Japan as a key commercial catalyst, while Signatera's recent EU Class C device certification and Japan PMDA approval expand its global regulatory footprint. Tempered enthusiasm comes from ongoing insider selling by co-founder Sheena Jonathan under a pre-planned 10b5-1 schedule, and analyst caution around continued cash burn and near-term reimbursement hurdles.

0.5781

July 17, 2026Natera shares declined amid a broader tech-driven market pullback, as the S&P 500 and Nasdaq slipped on renewed selling pressure in AI and chip stocks. Investor focus has also turned to a wave of insider selling — co-founder Sheena Jonathan executed over $836K in shares under a pre-planned Rule 10b5-1 trading plan and filed to sell an additional 1,500 shares, adding to the $85.96M in total insider sales recently flagged. Balancing the concern, new JAMA Oncology data showed Natera's Signatera MRD test can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy, reinforcing the clinical narrative ahead of key reimbursement decisions. Canaccord Genuity maintained its Buy rating and raised its price target to $330.

-2.7184

July 15, 2026Natera closed essentially flat as a bullish analyst catalyst took center stage: Canaccord Genuity raised its price target on the stock from $285 to $330, reiterating a Buy rating, citing confidence in the company's Signatera MRD platform and upcoming reimbursement and clinical trial catalysts. The upgraded target represents roughly 21% upside from current levels, reinforcing the narrative around Natera's expanding global footprint—including EU IVDR certification and Japan approval for Signatera in colorectal cancer—even as the broader healthcare sector (XLV) faced headwinds from mixed Q2 earnings results and macro uncertainty tied to Iran-related oil price spikes and Fed rate expectations.

-0.0843

July 14, 2026Natera edged higher Monday, outperforming the broader healthcare sector (XLV), even as markets navigated a risk-off session driven by renewed U.S.-Iran military strikes and surging oil prices. Investor focus on Natera centers on its Signatera MRD platform's expanding global footprint—including recent EU IVDR certification, NCCN guideline inclusion, and Japan approval for colorectal cancer—alongside upcoming 2026 reimbursement and trial catalysts. The stock has rallied sharply over the past three months (~46%), and analyst sentiment remains constructive with a median price target near $270, though some valuation models suggest the current premium already reflects much of the near-term upside.

1.0891

July 11, 2026Natera fell sharply, underperforming the broader healthcare sector (XLV closed modestly lower) and the S&P 500, even as the company announced a major regulatory milestone: Signatera became the first personalized MRD test for solid tumors to earn EU IVDR Class C certification, covering a broad range of cancers. Investors appear to be weighing whether this positive development is already priced in after a ~70% rally over the past year, with the stock trading above the median analyst price target and some valuation concerns flagged by multiple sources. Adding to the cautious sentiment, a pattern of heavy insider selling — totaling $85.96 million across executives over the past three months — continues to draw scrutiny, even as Morgan Stanley lifted its price target to $310 and consensus remains firmly at 'Buy.'

-4.2221

July 10, 2026Natera shares rose nearly 3%, approaching their 52-week high of $288.04, driven by a major catalyst: Morgan Stanley raised its price target from $250 to $310 while maintaining an Overweight rating, and the company announced EU IVDR Class C certification for its Signatera MRD test — expanding its commercial runway in Europe across multiple solid tumor types. Fresh clinical data published in JAMA Oncology and presented at the ESMO GI Congress further reinforced Signatera's value in guiding treatment decisions for colorectal liver metastases, while healthcare sector strength provided a constructive tailwind amid broader market resilience despite ongoing U.S.-Iran geopolitical tensions.

2.7188

July 9, 2026Natera shares fell amid a broad market risk-off session triggered by President Trump declaring the U.S.-Iran ceasefire 'over,' sending oil prices surging over 5% and stoking inflation fears. Company-specific headwinds compounded the move, with investors weighing a notable wave of insider selling — including $4.57M in shares sold by the Chief Legal Officer and ~$819K by the President of Clinical Diagnostics under pre-arranged 10b5-1 plans — alongside a board member resignation, pushing valuation concerns to the forefront despite positive Signatera MRD pipeline news.

-2.446

July 8, 2026Natera edged lower near its 52-week high as a wave of insider selling filings drew investor attention, including pre-planned Rule 10b5-1 sales by the CLO (~$4.57M) and Clinical Diagnostics President (~$819K) on July 1, alongside a Form 144 disclosure from co-founder Matthew Rabinowitz covering larger block sales in June. Offsetting the overhang, the company continues to build clinical momentum: new JAMA Oncology data showed Signatera MRD testing predicts chemotherapy benefit in colorectal liver metastases, Bernstein SocGen resumed coverage at Outperform with a $310 target, and the stock remains up ~79% over the past year.

-0.8915

Simply Wall Street · July 18, 2026Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully ValuedStock Titan · July 16, 2026New transplant policy would allow up to 12 rejection tests in year oneStock Titan · July 9, 2026EU clears Signatera for 10 cancer types under strict IVDR rulesStock Titan · June 24, 2026Japan approves Natera's Signatera for colorectal cancer patientsQuiver Quantitative · June 24, 2026Natera stock jumps as investors focus on fresh clinical data and strong growth outlookTradingView · May 8, 2026Why Natera (NTRA) Shares Are Plunging Today

Peers

S&P 500SPX · $7,457.69-1.01%Labcorp Holdings Inc.LH · $283.36+0.50%Quest Diagnostics IncorporatedDGX · $210.68+0.61%Illumina, Inc.ILMN · $186.65-1.89%Guardant Health, Inc.GH · $155.87+0.56%Myriad Genetics, Inc.MYGN · $6.18-0.16%CareDx, IncCDNA · $39.73-1.51%Fulgent Genetics, Inc.FLGT · $20.16-1.90%Fortrea Holdings Inc.FTRE · $17.76-0.89%Biora Therapeutics, Inc.BIORQ · $0.0002000.00%OPKO Health, Inc.OPK · $1.190.00%Thermo Fisher Scientific Inc.TMO · $532.48-1.97%